Development of Optical Biosensors for Diagnosis of Amyloid- β Peptide and Glial Fibrillary Acidic Protein

Protein (GFAP) levels in Cerebrospinal Fluid (CSF) and Blood plasma. Therefore, it is cardinal to understand some powerful analytical tools which have the capacity to identify even the smallest physiological change in sufferers' body in the level of A with great sensitivity. Since, collection of CSF via lumbar puncture is quite uncomfortable so blood based biosensing is an alternate approach for quantification, to overcome the drawbacks of routine screening programs. The detection limit of A peptide and GFAP has been found in the range 2.4-3.6 pg/ml and 0.2-0.5pg/ml of plasma respectively. It is believed that optical biosensing of blood-based biomarkers of the AD in the early diagnosis of AD will prove a milestone and give a jump to the disease therapeutics.